Grants & Funding

NIH-NHLBI-Logo.svg

Active Awards

1R21AG054211-01 (Akar FG)
Role: Principal Investigator
Agency: NIH/NIA
07/01/2016-06/30/2018
“Role of CCN5 in heart failure-related arrhythmias”
Priority Score 23, Percentile: 8.0
Total Costs: $466,125.00

1R01 HL113497 (Akar FG)
Role: Principal Investigator
Agency: NIH/NHLBI
04/01/2012 to 03/31/2017
“Role of STIM1 in cardiac hypertrophy and heart failure”
1R01HL119046-01 (Akar FG, Hajjar RJ)
Role: Principal Investigator, MPI
Agency: NIH/NHLBI
12/01/2013-12/31/2017
“Targeting abnormal calcium cycling using novel gene therapy vectors”
Total Costs: $2,935,216.00
AHA Grant-in-Aid: 13GRNT17000046 (Akar FG)
Role: Principal Investigator
Agency: American Heart Association
07/01/2013-06/30/2016
“Mitochondrial Targets in Cardiac Hypertrophy”
Total Costs: $198,000

Completed Awards 

1R21HL114378-01A1 (Akar FG)
Role: Principal Investigator
Agency: NIH/NHLBI
07/01/2013-06/30/2015       
“Regulating mitochondrial fission for arrhythmia prevention”  
Total Costs: $466,125.00
1 RO1HL091923-01 (Akar FG, Aon MA Paolocci P) 
Role: Principal Investigator, MPI
Agency: NIH/NHLBI         
01/01/2009 – 12/31/2013
“Mechanisms underlying mitochondrial dysfunction in the diabetic heart”
Total Costs: $2,034,000.00
1 R21-HL097108-01 (Akar FG)
Role: Principal Investigator
Agency: NIH/NHLBI         
07/01/2011 – 06/31/2013
“Integrative investigation of mitochondrial dysfunction”
Total Costs: $466,125.00
AHA SDG: 0830126N (Akar FG)
Role: Principal Investigator
Agency: American Heart Association
01/01/2008 – 12/31/2011
“Gap Junction Targets Modulating Transmural Repolarization and Arrhythmias in Chronic Ischemic Cardiomyopathy”
Total Costs: $308,000.00
Hirchl Award 08-1310 (Akar FG)
Agency: Imra T. Hirschl and Monique Weill-Caulier Trust
Role: Principal Investigator
01/01/2009-12/31/2013
“Novel imaging techniques for investigating arrhythmia mechanisms”
Total Costs: $175,000.00
1 P01 HL77180-01 (Kass DA)
Role: Co-PI on Project 2
Agency: NIH/NHLBI
07/01/2004-06/30/2009
“Pathobiology of Cardiac Dyssynchrony and Resynchronization”
Contract 07-0294 (Akar FG)
Role: Principal Investigator
Agency: Celladon Corporation
07/01/2007-06/30/2010      
“Effects of small molecules targeting SERCA2a/phospholamban interactions ”